Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief in serious diseases with high unmet medical need. More Details
Questionable track record with worrying balance sheet.
Share Price & News
How has Relief Therapeutics Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RLF is more volatile than 90% of Swiss stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: RLF's weekly volatility has decreased from 52% to 22% over the past year, but is still higher than 75% of Swiss stocks.
7 Day Return
1 Year Return
Return vs Industry: RLF exceeded the Swiss Biotechs industry which returned 1.3% over the past year.
Return vs Market: RLF exceeded the Swiss Market which returned -0.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Relief Therapeutics Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StWe Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide
3 months ago | Simply Wall StWe're Not So Sure You Should Rely on Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings
7 months ago | Simply Wall StRelief Therapeutics Holding (VTX:RLF) Is Making Moderate Use Of Debt
Is Relief Therapeutics Holding undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RLF's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RLF's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RLF is poor value based on its PE Ratio (488.1x) compared to the XE Biotechs industry average (43.3x).
PE vs Market: RLF is poor value based on its PE Ratio (488.1x) compared to the Swiss market (24.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RLF's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RLF is overvalued based on its PB Ratio (28.3x) compared to the CH Biotechs industry average (3x).
How is Relief Therapeutics Holding forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Relief Therapeutics Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of RLF’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Relief Therapeutics Holding competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Relief Therapeutics Holding performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RLF has a high level of non-cash earnings.
Growing Profit Margin: RLF became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: RLF has become profitable over the past 5 years, growing earnings by 44.6% per year.
Accelerating Growth: RLF has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RLF has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).
Return on Equity
High ROE: RLF's Return on Equity (5.6%) is considered low.
How is Relief Therapeutics Holding's financial position?
Financial Position Analysis
Short Term Liabilities: RLF's short term assets (CHF3.1M) do not cover its short term liabilities (CHF5.8M).
Long Term Liabilities: RLF's short term assets (CHF3.1M) do not cover its long term liabilities (CHF4.3M).
Debt to Equity History and Analysis
Debt Level: RLF's debt to equity ratio (14%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if RLF's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: RLF's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if RLF's interest payments on its debt are well covered by EBIT.
What is Relief Therapeutics Holding current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RLF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RLF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RLF's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RLF's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RLF's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Relief Therapeutics Holding has no CEO, or we have no data on them.
|CFO & Treasurer||0.25yr||no data||no data|
|Vice President of Finance & Administration||0.75yr||no data||no data|
|Chief Medical Officer||0.33yr||no data||no data|
|Chief Commercial Officer||0.083yr||no data||no data|
Experienced Management: RLF's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
|Chairman of the Board||4.67yrs||no data||no data|
|Director||1.58yrs||no data||no data|
|Director||0.083yr||no data||no data|
Experienced Board: RLF's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 53.6%.
Relief Therapeutics Holding AG's company bio, employee growth, exchange listings and data sources
- Name: Relief Therapeutics Holding AG
- Ticker: RLF
- Exchange: SWX
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF999.992m
- Shares outstanding: 3.25b
- Website: https://www.relieftherapeutics.com
Number of Employees
- Relief Therapeutics Holding AG
- Fondation EIP
- BAtiment F2/F3
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RLF||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Jul 2016|
|RLFT.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Jul 2016|
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief in serious diseases with high unmet medical need. The company focuses on clinical-stage programs based...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/16 18:05|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.